Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · IEX Real-Time Price · USD
22.50
+1.10 (5.14%)
At close: May 1, 2024, 4:00 PM
23.55
+1.05 (4.67%)
After-hours: May 1, 2024, 6:56 PM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 526 employees on December 31, 2023. The number of employees decreased by 72 or -12.04% compared to the previous year.
Employees
526
Change (1Y)
-72
Growth (1Y)
-12.04%
Revenue / Employee
$68,964
Profits / Employee
-$914,814
Market Cap
2.17B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 526 | -72 | -12.04% |
Dec 31, 2022 | 598 | 113 | 23.30% |
Dec 31, 2021 | 485 | 173 | 55.45% |
Dec 31, 2020 | 312 | 42 | 15.56% |
Dec 31, 2019 | 270 | 59 | 27.96% |
Dec 31, 2018 | 211 | 16 | 8.21% |
Dec 31, 2017 | 195 | 91 | 87.50% |
Dec 31, 2016 | 104 | 43 | 70.49% |
Dec 31, 2015 | 61 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Teladoc Health | 5,600 |
CONMED | 4,000 |
Amphastar Pharmaceuticals | 1,761 |
Inari Medical | 1,300 |
Deciphera Pharmaceuticals | 355 |
Sana Biotechnology | 328 |
TG Therapeutics | 264 |
Kymera Therapeutics | 187 |
NTLA News
- 2 days ago - Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 - GlobeNewsWire
- 6 weeks ago - Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy - GlobeNewsWire
- 2 months ago - Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 2 months ago - Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis - Business Wire
- 2 months ago - Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates - GlobeNewsWire
- 3 months ago - Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine - GlobeNewsWire
- 3 months ago - SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa - GlobeNewsWire
- 4 months ago - Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones - GlobeNewsWire